Literature DB >> 1081903

Improvement in delayed hypersensitivity in Hodgkin's disease with transfer factor: lymphapheresis and cellular immune reactions or normal donors.

A Khan, J M Hill, A MacLellan, E Loeb, N O Hill, S Thaxton.   

Abstract

Passive transfer of delayed hypersensitivity was achieved, with normal transfer factor, in patients with Hodgkin's disease in remission. The cellular immune responses of the recipients improved. It is suggested that, in addition to specific effect the transfer factor (or factors) has a nonspecific effect causing improvement in the state of delayed hypersensitivity of the recipient in general. The average number of E-rosette T lymphocytes was 46.3% after the transfer factor treatment in Hodgkin's disease. The control patients with Hodgkin's disease, not receiving transfer factor, had a value of 37.8%. Removal of 4.9 X 10(9) to 1.08 X 10(10) lymphocytes did not diminish the delayed hypersensitivity of the donor. Side effects attributable to transfer factor were not seen.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1081903     DOI: 10.1002/1097-0142(197507)36:1<86::aid-cncr2820360103>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  E-rosette inhibiting substance in Hodgkin's disease spleen extracts.

Authors:  M M Bieber; Z Fuks; H S Kaplan
Journal:  Clin Exp Immunol       Date:  1977-09       Impact factor: 4.330

2.  Immunocompetence and transfer factor therapy in uveitis.

Authors:  A Abramson; A Khan; G W Tate; R G Martin; N O Hill
Journal:  Br J Ophthalmol       Date:  1980-05       Impact factor: 4.638

3.  HIV-associated Hodgkin Lymphoma with a Granulomatous Bone Marrow Biopsy: A Case Report.

Authors:  Gil Hevroni; Zachary Mostel; Samara Skwiersky; Adam Osman; Moro O Salifu; Isabel M McFarlane
Journal:  Am J Med Case Rep       Date:  2020-11-27

4.  Rare Richter Transformation of Chronic Lymphocytic Lymphoma to Hodgkin Lymphoma.

Authors:  Tinera Buckley; Arati Inamdar; Nagyl H Mikhail; Abraham Loo; Seth Cohen
Journal:  Am J Case Rep       Date:  2021-12-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.